# BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

> **NCT04684654** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 118 (actual)

## Conditions studied

- Healthy Participants
- Primary Sjögren's Syndrome

## Interventions

- **BIOLOGICAL:** BMS-986325
- **OTHER:** Placebo for BMS-986325

## Key facts

- **NCT ID:** NCT04684654
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-16
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Insufficient enrollment
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684654, "BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04684654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*